Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info

Executive Summary

The US Food & Drug Administration is once again proposing a mandatory summary of key labeling information be dispensed with every prescription drug. Will the idea stay on the books this time?

You may also be interested in...



One-Page Patient Medication Information Document Moves Forward Under Proposed Rule

After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.

US Patient Medical Information Rule: Will It Be Delayed Again?

FDA originally proposed mandatory patient labeling in 1980 only to have the rule withdrawn by the incoming Reagan Administration; thirty-five years later, US agency is finalizing a proposed rule on the same topic. Will history repeat itself?

FDA OFFICES OF SUPPLEMENTAL APPROVALS WOULD BE ESTABLISHED BY AMENDED KASSEBAUM BILL; "MEDGUIDE" WOULD BE BLOCKED BY COATS AMENDMENT

FDA would be required to establish offices of supplemental approval in each of its centers under the version of Sen. Kassebaum's (R-Kan.) FDA reform bill that emerged from committee mark-up March 28. The provision is part of an amendment promoting the submission and approval of NDA supplements that was introduced by Sen. Kennedy (D-Mass.) and approved on a voice vote.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel